UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


 
FORM 8-K
 


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2021


 
PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)



Delaware
 
001-37568
 
26-4231384
(State or Other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)

25B Vreeland Road, Suite 300, Florham Park, NJ 07932
(Address of Principal Executive Offices, and Zip Code)

(800) 208-3343
Registrant’s Telephone Number, Including Area Code



(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered

Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐  No

Item 7.01
Regulation FD.

On June 7, 2021, PDS Biotechnology Corporation (the “Company”) updated its corporate presentation slide deck.  A copy of the slide deck is furnished as Exhibit 99.1 hereto.
     
Item 8.01
Other Events.

On June 8, 2021, the Company issued a press release announcing the presentation of interim data from the National Cancer Institute (NCI)-led Phase 2 trial at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. The press release is filed as Exhibit 99.2 hereto and incorporated herein by reference.

On June 8, 2021, the Company held a Post-ASCO Conference Call Interim Data Review.  A copy of the slide deck presented at this Conference call is filed as Exhibit 99.3 hereto and incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number
 
Description
     
 
Corporate Presentation June 7, 2021
 
Press Release, dated June 8, 2021.
 
Post-ASCO Conference Call Interim Data Review dated June 8, 2021.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PDS BIOTECHNOLOGY CORPORATION
     
Date: June 8, 2021
By:
/s/ Frank Bedu-Addo, Ph.D.
 
Name:
Frank Bedu-Addo, Ph.D.
 
Title:
President and Chief Executive Officer


PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more PDS Biotechnology Charts.
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more PDS Biotechnology Charts.